Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
lunedì, ottobre 05
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Rani Therapeutics Holdings Inc
RANI
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$0.7823
-0.0285
-3.52%
Ult. Agg.: Oct 5, 10:55 AM
$0.8430
0.0322
3.97%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Rani Therapeutics Hldgs Financials
Rani Therapeutics Hldgs (RANI) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Rani Therapeutics Hldgs Q2 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.708M Beat $925.000K Estimate
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 77.78 percent increase over losses of $(0.18) per share
Benzinga Newsdesk
PRO
Rani Therapeutics Hldgs Q1 EPS $(0.04), Inline, Sales $1.708M Beat $500.000K Estimate
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 81.82 percent increase over losses of $(0.22) per share from the same period last
Benzinga Newsdesk
PRO
Rani Therapeutics Hldgs Q4 EPS $(0.07) Misses $(0.06) Estimate, Sales $1.461M Miss $5.000M Estimate
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 22.81 percent. This is a 74.07 percent increase over losses of $(0.27) per
Benzinga Newsdesk
Earnings Scheduled For March 26, 2026
Benzinga Insights
PRO
Rani Therapeutics Hldgs Q3 EPS $(0.12) Beats $(0.15) Estimate
Cash, cash equivalents and marketable securities as of September 30, 2025 totaled $4.1 million, compared to $27.6 million for the year ended December 31, 2024. Rani expects its cash, and cash equivalents, including the
Benzinga Newsdesk
Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings
Avi Kapoor
